Drug profile · INN
drospirenone
LUCINDA
drospirenone (LUCINDA) is a progesterone receptor agonist. Route of administration: oral-28. Current US regulatory status: approved.
Drug details — drospirenone
- US status
- approved
- Class
- —
- Route
- ORAL-28
- Patents
- 4
- Programs
- 5
- Data quality
- 0.84
Quick answer
drospirenone (LUCINDA) is a progesterone receptor agonist. Route of administration: oral-28. Current US regulatory status: approved.
Key facts
Mechanism of action
Progesterone receptor agonist
Primary target: Mineralocorticoid receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 10420758
Indolinyl-sulfonamide inhibitors of tankyrase and methods of use thereof
granted -
US 6887675
Tankyrase H, compositions involved in the cell cycle and methods of use
expired -
US 6617102
Tankyrase H, compositions involved in the cell cycle and methods of use
expired -
US 6589725
Tankyrase H, compositions involved in the cell cycle and methods of use
expired
Frequently asked questions
What is drospirenone?
drospirenone (LUCINDA) is a progesterone receptor agonist. Route of administration: oral-28. Current US regulatory status: approved.
What is the brand name for drospirenone?
LUCINDA is a marketed brand name for drospirenone. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of drospirenone?
drospirenone has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.